Cabaletta Bio (CABA) vs Century Therapeutics (IPSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Cabaletta Bio (CABA) over the past year, gaining 137.8% versus a loss of 55.0%. Over five years, CABA leads with a -91.9% price change compared with -93.2% for IPSC. Century Therapeutics is the larger company by market cap ($211.6 million vs $201.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CABA | IPSC |
|---|---|---|
| Share price | $0.9361 | $1.17 |
| Market cap | $201.94M | $211.56M |
| 1-day change | -7.32% | -11.74% |
| YTD return | -57.26% | +17.09% |
| 1-year return | -55.00% | +137.76% |
| 5-year return | -91.93% | -93.23% |
| EPS (TTM) | $-1.33 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.16M |
| Revenue growth (YoY) | — | +1556.76% |
| Net income (latest FY) | $-167.86M | $-9.58M |
| Operating margin | — | -15.82% |
| Net margin | — | -8.78% |
| 52-week high | $4.23 | $3.04 |
| 52-week low | $0.93 | $0.48 |
| Distance from 52-week high | -77.87% | -61.68% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +1155.21% | +307.73% |
| Average volume | 5.15M | 759.69K |
| Shares outstanding | 215.72M | 181.60M |
| Employees | 154 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed CABA by 192.8 percentage points over the past year.
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
CABA vs IPSC FAQ
Which is bigger, Cabaletta Bio or Century Therapeutics?
Century Therapeutics (IPSC) is larger, with a market capitalization of $211.56M compared with $201.94M for Cabaletta Bio (CABA).
Which stock has performed better over the past year, CABA or IPSC?
IPSC returned +137.76% over the past 12 months, compared with -55.00% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Cabaletta Bio and Century Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.